mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations

BACKGROUND: Cetuximab, a monoclonal blocking antibody against the epidermal growth factor receptor EGFR, has been approved for the treatment of squamous cell carcinomas of the head and neck (HNSCC). However, only few patients display long-term responses, prompting the search for cetuximab resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhiyong, Martin, Daniel, Molinolo, Alfredo A., Patel, Vyomesh, Iglesias-Bartolome, Ramiro, Sol Degese, Maria, Vitale-Cross, Lynn, Chen, Qianming, Gutkind, J. Silvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133928/
https://www.ncbi.nlm.nih.gov/pubmed/25099740
http://dx.doi.org/10.1093/jnci/dju215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133928/
https://www.ncbi.nlm.nih.gov/pubmed/25099740
http://dx.doi.org/10.1093/jnci/dju215

Ejemplares similares